In the Pipeline

  • Myogen has begun patient enrollment in Phase III clinical trials of ambrisentan for the treatment of pulmonary arterial hypertension.
  • Genome Sciences has begun dosing patients in a Phase II clinical trial of human monoclonal antibody to B-lymphocyte stimulator, BlyS (LymphoStat-B), for the treatment of rheumatoid arthritis.
  • Favrille has completed enrollment for its current Phase II clinical trial (FavId-04) with the company’s lead investigational agent, FavId. This agent is under clinical development for the treatment of follicular B-cell lymphomas following cytoreductive therapy with Rituxan.
  • Cytheris has announced the entry of its first recombinant human Interleukin-7 protein in a Phase I clinical study. This cytokine targets the immune reconstitution of immunocompromised patients, including those undergoing cancer treatment, affected by AIDS, or recovering from a bone marrow transplant.
  • Coley Pharmaceutical Group has initiated a Phase I clinical study of CPG 10101 (Actilon), a novel synthetic TLR9 agonist, targeted for patients with chronic hepatitis C infection.
  • Peninsula Pharmaceuticals has announced that patient enrollment has begun in a Phase I trial of an inhaled formulation of its lead product candidate, doripenem, a broad-spectrum carbapenem antibiotic.
  • Epimmune has completed patient enrollment in the Phase I/II therapeutic HIV vaccine trial of its EP HIV-1090 vaccine candidate.
  • Progen Industries Limited has begun a new Phase II clinical study of its lead anticancer compound, PI-88.
  • Pharmacyclics has initiated a Phase I clinical trial evaluating the safety and efficacy of its investigational drug motexafin gadolinium (Xcytrin) in combination with temozolomide (Temodar) for the treatment of patients with relapsed malignant gliomas.
  • Allos Therapeutics has initiated a Phase I clinical trial of efaproxiral (RSR13) and supplemental oxygen with concurrent chemoradiation therapy in patients with locally advanced, unresectable (Stage IIIA/Stage IIIB) non-small cell lung cancer.
  • Genencor International is beginning Phase I safety and immunogenicity testing for its DNA-based therapeutic vaccine to treat hepatitis B.